Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
NCT01573052 is a phase 4 interventional trial sponsored by VA Salt Lake City Health Care System. As of 21 Nov 2026, it is completed. It studies Chlordiazepoxide and Gabapentin in Alcohol Withdrawal. The registry lists an enrollment of 26 participants at 1 site in 1 country. The registry lists a start date of 31 Mar 2004 and a primary completion date of 31 Aug 2010.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01573052 |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | VA Salt Lake City Health Care System |
| Enrollment | 26 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Alcohol Withdrawal |
| Drugs | Chlordiazepoxide and Gabapentin |
| Start | 31 Mar 2004 |
| Primary completion | 31 Aug 2010 |
| Study completion | 30 Sept 2010 |
| Last update posted | 17 Aug 2020 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Christopher J Stock, PharmD
Salt Lake VA Health Care System
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- George E Wahlen Va Medical Center
Salt Lake City
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01573052
Each answer restates registry values shown on this page.
What is NCT01573052?
NCT01573052 is a phase 4 interventional trial sponsored by VA Salt Lake City Health Care System. It studies Chlordiazepoxide and Gabapentin in Alcohol Withdrawal.
Who leads NCT01573052?
The registry names Christopher J Stock, PharmD (principal investigator, Salt Lake VA Health Care System) as the overall official.
Where does NCT01573052 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01573052 study?
The registered drug and biological interventions are Chlordiazepoxide and Gabapentin.
When did NCT01573052 end?
The registry lists a primary completion date of 31 Aug 2010 and a study completion date of 30 Sept 2010. The sponsor last updated the record on 17 Aug 2020.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.